



June 6, 2002

## **Roche and Genmab Announce Major Expansion of Antibody Collaboration**

### **Roche to Invest \$20Million in Genmab**

**Basel, Switzerland and Copenhagen, Denmark; June 6, 2002** - Roche and Genmab A/S (CSE: GEN and Neuer Markt: GE9D) announced today a broad expansion of their current collaboration with Genmab for the creation and development of human antibody therapeutic products for life-threatening and debilitating diseases. Roche is also making an equity investment totaling \$20 Million (approximately DKK 170 Million) at a price of DKK 180 per share.

This expanded program involves a number of new disease targets from Roche. Genmab expects to initiate approximately fifteen new projects in the coming year across a number of therapeutic areas. The program is coordinated by Roche's proteomics group and will focus on the company's commitment to the development of biologicals as innovative new products.

Under the current agreement Roche has access to Genmab's antibody development capabilities as well as its pre-clinical and clinical development capabilities and Genmab will receive milestones as well as royalty payments on successful products. In certain circumstances Genmab could obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration could be as high as \$100 Million.

"Our alliance with Genmab has the potential to significantly strengthen our position in this important field. We are pleased to further expand our global programmes to create and develop important new antibody medicines with Genmab as an important partner," Said Jonathan Knowles, Head of Global Pharmaceutical Research at Roche.

"The expansion of our existing program underlines the strength of our organization and expertise we can provide for such a valuable partner as Roche," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We look forward to continuing to work together with Roche in order to strengthen Genmab's broad portfolio of products in development."